Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Globe Newswire•05/10/2026•08:00 ET
0
Key Highlights
- ➤ESMO 2026 features four Celcuity gedatolisib presentations, including one late-breaking oral session
- ➤VIKTORIA-1 reports updated PIK3CA mutant-type subgroup analyses in HR+/HER2- advanced breast cancer
- ➤Comparative PIK3CA wild-type analysis evaluates gedatolisib against other post-CDK4/6i regimens
- ➤Gedatolisib plus darolutamide subgroup data presented from an mCRPC Phase 1b trial
- ➤VIKTORIA-2 Phase 3 first-line trial presentation evaluates gedatolisib, endocrine therapy, and palbociclib
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort
Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer
Get started
Create a free account to read the full story.